Xiaomin Fu

100 Kexue Road
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.

Journal: Scientific reports

Published: February 27, 2025

Corrigendum to "CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma" [Mol. Immunol. 172 (2024) 76-84].

Corrigendum to "CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma" [Mol. Immunol. 172 (2024) 76-84].

Journal: Molecular immunology

Published: October 29, 2024

CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma.

CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma.

Journal: Molecular immunology

Published: March 06, 2024

Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer.

Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer.

Journal: Cancer innovation

Published: December 21, 2023

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study.

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study.

Journal: Immunity & ageing : I & A

Published: June 10, 2023

Retraction Note to: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner.

Retraction Note to: Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner.

Journal: Molecular cancer

Published: August 09, 2022

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.

Journal: Frontiers in immunology

Published: February 23, 2022

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer.

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer.

Journal: Frontiers in oncology

Published: January 11, 2022

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.

Journal: Frontiers in immunology

Published: September 18, 2021

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.

Journal: Frontiers in immunology

Published: September 08, 2021

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.

Journal: The oncologist

Published: July 06, 2021

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.

Journal: BMC gastroenterology

Published: May 03, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026